Anticoagulant

Clopidogrel (Noklot) Tablet

$70.00

Clopidogrel is an antiplatelet medication that works by irreversibly inhibiting the P2Y12 adenosine diphosphate (ADP) receptor on platelets. This prevents platelets from sticking together and forming blood clots, thereby reducing the risk of thrombotic events such as heart attack and stroke.

Quantity

Clopidogrel (Noklot) Tablet quantity

Add to cart

Tag:

Clopidogrel Noklot

Description

Clopidogrel Noklot Tablet is a medication used in the prevention of cardiovascular events such as heart attack and stroke. It contains clopidogrel as its active ingredient, which belongs to a class of drugs known as antiplatelet agents. Clopidogrel works by inhibiting platelet aggregation, thereby reducing the risk of blood clots that can lead to cardiovascular events.

Key Features:

• Antiplatelet Agent: Clopidogrel is an antiplatelet medication that works by irreversibly inhibiting the P2Y12 adenosine diphosphate (ADP) receptor on platelets. This prevents platelets from sticking together and forming blood clots, thereby reducing the risk of thrombotic events such as heart attack and stroke.
• Prevention of Cardiovascular Events: Clopidogrel Noklot Tablet is indicated for the prevention of cardiovascular events in patients with a history of myocardial infarction (heart attack), ischemic stroke, or peripheral arterial disease. It is also used in patients with acute coronary syndrome, including unstable angina and non-ST segment elevation myocardial infarction (NSTEMI).
• Oral Administration: Clopidogrel Noklot Tablet is administered orally, typically once daily, with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Efficacy: Clinical trials have demonstrated the efficacy of clopidogrel in reducing the risk of cardiovascular events, including heart attack, stroke, and cardiovascular death, in patients at risk. It is often used in combination with aspirin for dual antiplatelet therapy to further reduce the risk of thrombotic events.
• Side Effects: Common side effects associated with clopidogrel may include bleeding, bruising, gastrointestinal upset, and rash. Patients should be closely monitored for signs of bleeding, and healthcare providers should be informed of any unusual bleeding or bruising.
• Patient Education: Patients prescribed Clopidogrel Noklot Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
• Consultation with Healthcare Provider: Treatment with Clopidogrel Noklot Tablet should be initiated and monitored by a qualified healthcare provider experienced in the management of cardiovascular disease. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Clopidogrel Noklot Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to effective cardiovascular medications is crucial to improving patient outcomes and quality of life.